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Fatty acid amide hydrolase (FAAH) is a mammalian integral membrane enzyme that terminates the activity of a large class of endogenous signaling lipids termed the fatty acid amides (1) (2) (3) . Representative fatty acid amides degraded by FAAH include the endogenous cannabinoid N-arachidonoyl ethanolamine (anandamide) (4), the antiinflammatory substance N-palmitoyl ethanolamine (5) , and the sleep-inducing lipid 9Z-octadecenamide (oleamide) (6). The central role that FAAH plays in regulating fatty acid amide signaling in vivo has been revealed by studies of rodents in which this enzyme has been genetically and/or chemically inactivated. For example, mice with a targeted disruption of the FAAH gene [FAAH(-/-) mice] possess dramatically elevated endogenous levels of fatty acid amides in the central nervous system (7, 8) , resulting in a cannabinoid receptor 1 (CB1)-dependent reduction in pain sensation (7, 9) . Similarly, administration of FAAH inhibitors to rodents causes a significant increase in brain levels of fatty acid amides that correlates with CB1-mediated anxiolytic and analgesic effects in these animals (10) .
Thus, animal studies indicate that FAAH serves as the primary catabolic regulator of fatty acid amide signaling in the nervous system and, therefore, may play an important role in modulating a variety of neurobehavioral processes. To probe potential functional links among FAAH, the endocannabinoid system, and disorders of the human nervous system, we recently conducted a search for mutations in the human FAAH gene in subjects with neurobehavioral disorders. These studies identified a single nucleotide polymorphism (SNP) in the FAAH gene (385C to A) that in homozygous form was significantly associated with both street drug use and problem drug/alcohol use (11) . This mutation 4 converts a conserved proline residue P129 to threonine, suggesting that it may produce a functional change in FAAH and, by extension, the endocannabinoid signaling system. Nonetheless, whether subjects with the 385A polymorphism express a FAAH protein with abnormal properties remains unknown. Here, we compare the expression and activity of the wild type (WT) and P129T human FAAH proteins in both peripheral Tlymphocytes and transfected cells. Collectively, these studies reveal that the P129T-FAAH variant is constitutively expressed at lower levels and activity than WT-FAAH due to differential post-translational regulation, thus providing the first biochemical evidence that subjects with the 385A mutation possess functional alterations in the endocannabinoid signaling system.
Results
Analysis of FAAH expression and activity in circulating T-lymphocytes from human subjects with wild type and 385A/385A FAAH genes. The 385C to A polymorphism in the human FAAH gene associated with problem drug use converts a proline residue P129 to threonine. Notably, this amino acid, which resides on a surface loop on the cytoplasmic face of FAAH ( Figure 1A ) (12) , is completely conserved among all of the mammalian FAAH proteins identified to date ( Figure 1B ) (13), suggesting that it may be important for the structure and/or function of the enzyme. However, in initial studies, the purified WT-and P129T-FAAH proteins were found to exhibit similar catalytic properties and structural stability, with the only detectable difference being a slightly faster rate of trypsin proteolysis for the P129T mutant (11) . Thus, the potential impact, if at Pennsylvania State University on http://hmg.oxfordjournals.org/ Downloaded from 5 any, of the P129T mutation on the function of human FAAH in vivo has remained obscure. To address this question, we isolated peripheral circulating T-lymphocytes from wild type and 385A/385A human subjects and measured FAAH expression and activity in these cells. Interestingly, 385A/385A lymphocytes expressed less than half of the FAAH activity found in wild type lymphocytes (Figure 2A ). This lower amount of FAAH activity correlated with a similar reduction in FAAH protein as estimated by western blotting using anti-FAAH polyclonal antibodies ( Figure 2B ). Thus, these initial experiments revealed that the P129T FAAH mutant is expressed at significantly lower levels than WT-FAAH in primary human T-lymphocytes. Figure 3C ). Thus, in both human T-lymphocytes and transfected cells, the P129T FAAH mutant was expressed at significantly lower levels than WT-FAAH. In contrast, transfected cells were found to express equivalent levels of WT-and P129T-FAAH mRNA ( Figure 3D ), indicating that the reduced expression of the 6 P129T FAAH protein was due to a post-transcriptional and/or post-translational mechanism.
The reduced cellular expression of P129T-FAAH is due to a post-translational mechanism. To examine whether the reduced expression of P129T-FAAH was due to a defect in the translation of the mRNA encoding this mutant protein, we compared the levels of WT-and P129T-FAAH protein produced by in vitro translation using a rabbit reticulocyte extract supplemented with dog microsomes. Equivalent levels of both proteins were generated in this assay (Figure 4 ), indicating that the reduced expression of P129T-FAAH was not due to a defect in translation.
The reduced expression of P129T-FAAH could be due to an enhanced rate of cellular turnover. Indeed, potentially consistent with this idea, P129T FAAH was found previously to show enhanced sensitivity to trypsin proteolysis in vitro (11) 8
Discussion
The central cannabinoid (CB1) receptor is the primary site of action in the nervous system for ∆ 9 -tetrahydrocannabinol, the psychoactive component of marijuana (19) . The elevate the levels of this protein, it is possible that its degradation is mediated by other proteases that are insensitive to these inhibitors. In this regard, proteasome-independent pathways for degradation have been described for several intracellular proteins (27) (28) (29) .
In summary, this manuscript describes the first evidence that the natural 385A SNP in the human FAAH gene associated with problem drug use produces a mutant enzyme (P129T-FAAH) with defective biochemical and cellular properties. Given that reduced levels of the P129T FAAH enzyme were observed in both primary (human T-lymphocytes) and transfected (COS-7) cells, we suggest that defective expression may prove to be a general feature of this mutant protein, and, therefore, human subjects homozygous for the 385A mutation may possess constitutively lower levels of FAAH activity in both central and peripheral tissues. Although it is tempting to speculate that these subjects may display a corresponding increase in endocannabinoid signaling that contributes, at least in part, to their drug use problems, further studies are needed to address this important issue.
Indeed, drug addiction and dependence are highly complex traits that are undoubtedly influenced by many genetic and environmental factors (30), and it is important to emphasize that the 385A SNP is also prevalent in human subjects that do not display any apparent problems with drug use (11) . Regardless, the finding that a common natural mutation in the human FAAH gene produces an enzyme with altered expression and activity highlights that significant functional variability exists in the endocannabinoid system in the human population. Future studies aimed at establishing links between alterations in endocannabinoid signaling and behavior should increase our understanding of the role that this important lipid transmitter system plays in human physiology and pathology.
Materials and Methods
Research subjects. Anonymous blood donors who agreed with informed consent to participate in genetics research were genotyped for the FAAH 385 alleles by methods described previously (11) . In a survey of 163 regular anonymized blood donors, eleven FAAH 385 A/A subjects were identified and paired with FAAH 385 C/C control subjects based on matching age, gender, medication use and ethnicity for blinded assays in groups of 2 to 4. Whole blood samples (100 mL) were collected from each subject and peripheral T lymphocytes were isolated as described below. This protocol was approved by the local institutional review board, and all subjects signed informed consent documents. Northern blot analysis. RNA samples for Northern blotting were isolated from FAAHtransfected COS-7 cells. Cells were harvested in room temperature Trizol R buffer (Gibco) and total cellular RNA was isolated according to manufacturer's guidelines. Representative western blot analysis of T-lymphocyte membrane fractions from paired subject samples using anti-FAAH polyclonal antibodies (31). 
